New Stock News | Sirio Pharma (300791.SZ) submits application to Hong Kong Stock Exchange, ranking first in the Chinese nutrition and health food solution market.

According to the disclosure by the Hong Kong Stock Exchange on January 29th, Sirio Pharma Technology Co., Ltd. (referred to as Sirio Pharma, 300791.SZ) has submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CITIC SEC as its exclusive sponsor. Company Overview According to the prospectus, the company is a leading provider of nutritional health food solutions. Based on data from Brightfield Consulting, by 2024, the company occupies the third largest market share in the global nutritional health food solution market, and ranks first in the Chinese market. In addition, based on Brightfield Consulting's data, by 2024, the company ranks as the second largest provider of gummy and soft capsule nutritional health food solutions in the world. With a focus on the huge potential market of nutritional health food solutions, the company's business performance has achieved steady growth and sustainable development. Established in 1993, with a deep understanding of health demands, the company's strategic focus has gradually shifted from pharmaceuticals to the field of nutritional health foods. Over the past 33 years of vigorous development, the company has established a comprehensive solution portfolio, covering a wide range of products for all demographics and receiving support from a diversified customer base across multiple business models. The company is a pioneer in establishing a global business layout in the nutritional health food solution market, with globally integrated and locally responsive production bases, research centers, and supply chain networks. With its strong research and production capabilities, combined with excellent operational efficiency supported by global resources, the company is able to continuously provide end-to-end solutions to global customers, covering market insights, customized solutions, differentiated research and development, global production capabilities, industry-wide collaboration, and marketing empowerment. With insights into the market, the company has established a comprehensive and three-dimensional solution portfolio to provide customers with one-stop solutions that precisely meet the diverse needs of different types of customers across various industries. The company's board of directors consists of nine directors, including three executive directors, two non-executive directors, and four independent non-executive directors. Directors serve a term of three years and are eligible for re-election. Ownership Structure As of the latest feasible date (January 21, 2026), Mr. Lin and Ms. Chen (Mr. Lin's spouse) respectively hold 59% and 11% of the equity in Glorious Investment. Therefore, according to the Securities and Futures Ordinance, Mr. Lin and Ms. Chen are deemed to have interests in all the shares held by Glorious Investment. As of the latest feasible date, Ms. Chen and Abama Happy Dividend No. 96 are considered as acting in concert regarding their shareholding in the company. Therefore, according to the Securities and Futures Ordinance, both Ms. Chen and Abama Happy Dividend No. 96 are deemed to have interests in each other's shareholding. As of the latest feasible date, the company's share buyback account holds 1,285,600 repurchased A shares, accounting for approximately 0.42% of the total issued A shares. As of the latest feasible date, Mr. Lin, Ms. Chen, Glorious Investment, and Abama Happy Dividend No. 96 directly and indirectly control more than one-third of the voting rights at the company's general meeting and are deemed to have interests in the repurchased A shares held by the company. Mr. Lin holds the equity of Glorious Investment and company shares previously held by the late Mr. Lin Qixiong through a testamentary trust arrangement named Lin Gaofu Legacy Trust. Intermediary Team Exclusive Sponsor: CITIC SEC (Hong Kong) Limited; Legal Advisors: Gallant Y.T. Ho & Co., King & Wood Mallesons; Exclusive Sponsor and Compiling Legal Advisors: Howse Williams Bowers, Howse Williams Lawyers; Auditors and Reporting Accountants: Deloitte Touche Tohmatsu; Industry Consultants: Brightfield Consulting Limited; Compliance Advisors: SOMERLEY CAP Limited.